



KHRS 2023


The Impact of Low Posterior Left Atrial Wall Voltage on the Outcomes of Catheter Ablation for Persistent Atrial Fibrillation

David Chieng

Alfred Hospital, Melbourne

Baker Heart and Diabetes Institute, Melbourne

University of Melbourne





KHRS 2023


Declaration Of Interest

- No relevant disclosure




Introduction

- **Pulmonary vein isolation (PVI)**: less effective in persistent AF
 - Adjunctive ablation strategies – did not improve outcomes over PVI alone
- **Atrial fibrosis**: structural remodelling and substrate
 - Late gadolinium enhancement(LGE) on cardiac MRI
 - Low voltage areas(LVA) on EAM: <0.5 mV
- **Low voltage areas**
 - Increased arrhythmia recurrence post catheter ablation





Introduction



No. at risk					
MRI-guided	407	277	251	114	64
PVI only	408	284	249	118	69

DECAAF II

- PVI + MRI-guided atrial fibrosis ablation (421 patients)


Vs

- PVI alone (422 patients)

HR 0.95 [95% CI, 0.77-1.17]; $P = .63$



Introduction




ERASE AF


- PVI + substrate modification (161)
Vs
• PVI alone (163)

HR 0.62 [95% CI, 0.43-0.88]; $P = .006$

Prevalence of LVA in SM group : 34%



Introduction



CAPLA

- PVI + Posterior wall isolation (170)
- PVI alone (168)

Vs

HR 0.99 [95% CI, 0.73-1.36]; P= .98



Aims



- To examine the outcomes of catheter ablation as determined by the presence or absence of posterior wall LVA




Methods

- Pre-specified subgroup analysis
- CAPLA : Multi-centre, international, randomized controlled study
 - Australia, Canada, UK

Inclusion Criteria	Exclusion Criteria
<ol style="list-style-type: none">1. Persistent AF: AF >7 days2. First-time ablation procedure3. Symptomatic AF refractory to anti-arrhythmic drug (AAD)	<ol style="list-style-type: none">1. Paroxysmal AF2. Long-standing persistent AF >3 years3. AF secondary to reversible cause4. Contraindication to anticoagulation5. End stage renal or hepatic failure6. Severe valvular heart disease7. Hypertrophic cardiomyopathy




PVI ONLY



PVI + PWI


- GA, TOE guided trans-septal puncture
- Contact force sensing irrigated RF catheter: 40-50W ; target LSI or AI
- Oesophageal temperature monitoring



Methods


Electroanatomic mapping


- Patients included : sinus rhythm at the time of ablation/ successful cardioversion following transseptal access
- LA voltage mapping at CSd 600ms
- CARTO (Biosense Webster), or Ensite Precision/ Velocity (Abbott Medical
 - High density mapping - minimum of 1,000 evenly distributed mapping
 - Acquired points - manually reviewed off line and annotated



Methods

- Left atrium – divided into segments:
 - Anterior
 - Posterior
 - Roof
 - Inferior
 - Left and right PV antrum
- Bipolar voltage
 - Low-voltage area(LVA): <0.5 mV
 - Scar: <0.05 mV
- Surface area of LVA - manually measured on CARTO/Ensite systems





Methods

Post ablation management


- Anti arrhythmic drug
 - Discontinued at 3 months
 - Amiodarone - discontinued prior to ablation and not restarted
- Clinical reviews - 3 months, and 12 months post ablation
- Phone/ Telehealth consultations - 6 weeks, 6 months, 9 months post ablation



Methods

Cardiac rhythm monitoring

- Implantable loop / intracardiac device
- Twice daily ECGs with Alive Cor device
 - Additional ECGs for symptoms
- 24 hour Holter 3, 6, 9,12 months post ablation
 - If non-compliant with ECG monitoring
- Arrhythmia events: blinded adjudication




Endpoints

- **Primary:**
 - Freedom from any documented atrial arrhythmia of >30 seconds, at 12 months follow up after a single ablation procedure off AAD, **in patients with posterior LVA**, who underwent PVI with PWI compared to PVI alone
- **Secondary:**
 - Posterior LVA and correlation with other atrial LVA
 - Effects of adding PWI to PVI in **patients with posterior LVA**, compared to PVI alone, on freedom from any arrhythmia after **multiple ablation** procedures, on or off AAD
 - Arrhythmia recurrence outcomes in patients **with and without posterior LVA**



Results

Posterior LVA prevalence:
69 (32.9%)






Results

	Additional LA segment(s) with evidence of LVA	P value
Posterior wall LVA	51/56 (91.7%) <ul style="list-style-type: none">• Inferior (56.5%)• Anterior (52.2%)• Left antrum(27.5%)• Right antrum (24.6%)• Roof (23.2%)	P<0.01
No posterior wall LVA	56/98 (57.1%)	




KHRS 2023

Primary Outcome




Freedom from any arrhythmia (%)

Lowest Quartile



Freedom from any arrhythmia (%)


3rd Quartile



No. at risk

Freedom from any arrhythmia (%)


2nd Quartile



No. at risk


Freedom from any arrhythmia (%)

Highest Quartile




No. at risk

LVA on posterior left atrial wall and ≥ 1 other LA segment




Multiple ablation procedures in patients with posterior LVA






Posterior LVA vs No Posterior LVA




Presence of posterior LVA was associated with higher risk of arrhythmia recurrence



Posterior LVA (Quartiles)




Increasing burden of posterior LVA was associated with progressively higher risk of arrhythmia recurrence



Limitations

- 38% of original cohort - excluded
 - In particular early AF recurrence following cardioversion
- Low voltage on endocardial mapping
 - ? Adipose
 - Affected by the direction of activation of the waveform
 - Dynamic atrial substrate when pacing from different atrial sites (Wong et all JACC Clin Electrophysiol 2018)



Conclusions

- 1) In patients with PsAF undergoing catheter ablation, the presence of posterior LVA was associated with a significant increase in atrial arrhythmia recurrence**

- 2) However, the addition of PWI in those with posterior LVA did not result in a significant improvement in atrial arrhythmia recurrence outcomes.**



KHRS 2023

Acknowledgements



Co-authors: Peter M Kistler, Hariharan Sugumar, Liang-Han Ling, Sandeep Prabhu, Aleksandr Voskoboinik, Ahmed Al-Kaisey, Ramanathan Parameswaran, Robert D Anderson, Joshua Hawson, Louise Segar, Sue Finch, Geoffrey Wong, Joseph B Morton, Bhupesh Pathik, Alex J McLellan, Geoffrey Lee, Michael Wong, Rajeev K Pathak, Deep Chandh Raja, Laurence Sterns, Matthew Ginks, Christopher M Reid, Prashanthan Sanders and Jonathan M Kalman

